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Tumour cell lines are commonly used in colorectal cancer (CRC) research, including studies designed to assess methylation defects.
Although many of the known genetic aberrations in CRC cell lines have been comprehensively described, no studies have been
performed on their methylation status. In this study, 30 commonly used CRC cell lines as well as seven primary tumours from
individuals with hereditary nonpolyposis colorectal cancer (HNPCC) were assessed for methylation at six CpG islands known to be
hypermethylated in colorectal cancer: hMLH1, p16, methylated in tumour (MINT-)-1, -2, -12 and -31. The cell lines were also
assessed for microsatellite instability (MSI), ploidy status, hMLH1 expression, and mutations in APC and Ki-ras. Methylation was
frequently observed at all examined loci in most cell lines, and no differences were observed between germline-derived and sporadic
cell lines. Methylation was found at MINT 1 in 63%, MINT 2 in 57%, MINT 12 in 71%, MINT 31 in 53%, p16 in 71%, and hMLH1 in
30% of cell lines. Overall only one cell line, SW1417, did not show methylation at any locus. Methylation was found with equal
frequency in MSI and chromosomally unstable lines. MSI was over-represented in the cell lines relative to sporadic CRC, being
detected in 47% of cell lines. The rate of codon 13 Ki-ras mutations was also over three times that expected from in vivo studies. We
conclude that CpG island hypermethylation, whether acquired in vivo or in culture, is a ubiquitous phenomenon in CRC cell lines. We
suggest that CRC cell lines may be only representative of a small subset of real tumours, and this should be taken into account in the
use of CRC cell lines for epigenetic studies.
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It is generally accepted that colorectal cancer (CRC) usually
develops via one of two pathways–chromosomal instability
(Kinzler and Vogelstein, 1996) or microsatellite instability (MSI)
(Ionov et al, 1993). The molecular genetics of both these pathways
are among the best understood of all human cancers. Recently,
a third classification of CRC has emerged–the CpG island
methylator phenotype (CIMP) (Toyota et al, 1999a). This
classification is primarily based on the methylation status of
certain sites in the genome, termed MINT loci, which
are preferentially methylated in tumours. CIMP tumours are a
subset of CRC with distinct clinicopathological characteristics and
have been found to be associated with MSI (Ahuja et al, 1997;
Hawkins et al, 2002).
Cell lines are widely used in CRC research, including studies on
methylation, and are generally thought to be representative of the
disease. Several groups have studied many commonly used cell
lines at the genetic level, and generally the genetic changes in cell
lines do reflect the changes seen in vivo (Ilyas et al, 1997; Rowan
et al, 2000; Gayet et al, 2001; Woodford-Richens et al, 2001).
However, despite the increased use of colorectal cell lines for
epigenetic studies, there have been no comprehensive studies of
the propensity for methylation in these cell lines.
In this study, we have examined the methylation status of four
informative MINT loci, and the p16 and hMLH1 promoter, in 30
commonly used CRC cell lines. The aim of this study was to
determine the frequency of CpG island hypermethylation in these
cell lines, and determine if the epigenetic profile of these cell lines
reflects that seen in primary colorectal tumours.
MATERIALS AND METHODS
Methylation frequency in the set of sporadic tumours reported in
the analysis was determined in a previous study of 417
prospectively collected tumours (Hawkins et al, 2002). Also
included in the current analysis were seven primary tumours
from seven individuals with a proven germline mutation in a
mismatch repair gene (five hMSH2 and two hMLH1). These
primary tumours were collected as fresh representative tissue
samples from consenting individuals undergoing surgical resection
at the St Vincent’s Campus. The 30 human colorectal cell lines
examined in this study are listed in Table 1. All cell lines were
either originally derived from the ATCC, or received as kind gifts.
Cells were cultured in DMEM, EMEM or RPMI, all supplemented
with 10% foetal calf serum, and were harvested when growing
exponentially. DNA was extracted from fresh tissue and cell lines
using standard methods. Received 26 September 2002; accepted 9 October 2002
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(Rowan et al, 2000). Mutations in the first and second bases
of codon 12 of Ki-ras were detected by REMS-PCR as described
(Ward et al, 1998). An RFLP method was developed for
the detection of Ki-ras codon 13 mutations. Genomic DNA
(500ng) was used in PCR with 0.5mM of each of the primers
50-ATATAAACTTGTGGTAGTTCCAGCTGGT-30 and 50-ATCAAA-
GAATGGTCCTGCACC-30, 2.5mM MgCl2, 100mM dNTPs, 1.25U
FastStart TaqDNA polymerase (Roche Diagnostics GmBH, Man-
nheim, Germany) in the reaction buffer provided by the
manufacturer. PCR cycling conditions were as follows: 951C
for 5min; 10 cycles of 951C for 20s, 701C for 20s with a
touchdown of 11C per cycle; followed by a further 32 cycles of 951C
for 20s, 601C for 20s, 721C for 30s prior to a final extension
at 721C for 4min. Restriction fragment length polymorphism
(RFLP) analysis was performed on amplicons at 551C for 16h
with 10U of BslI (NEB) according to the manufacturer’s
instructions. The resistance of PCR amplicons to BslI digestion
indicated the presence of a mutation at the first or second base of
Ki-ras codon 13.
The presence of MSI in each cell line was determined essentially
as described (Hawkins and Ward, 2001) using primer sets for the
pseudomonomorphic markers Bat25, Bat26 and Bat40 (Boland
et al, 1998).
Assessment of ploidy was performed using the method of Taylor
(1980). Briefly, washed tumour cells (2.5 10
6) were incubated at
41C for 10min with a 1% Triton X-100 solution containing
100mgml
 1 of propidium iodide (Sigma, St. Louis, USA) in PBS.
Cells were filtered through a nylon mesh to remove any clumps
and incubated with DNAse-free RNAse for 30min at 41C before
analysis on the flow cytometer.
For methylation analyses, DNA was treated with sodium
bisulphite and methylation-specific PCR (MSP) was performed to
detect methylation of the p16 promoter region (Herman et al, 1998;
Hawkins et al, 2002). The methylation status of MINT 1, 2, 12 and
31 was performed according to the method of Toyota et al (1999a),
and modified as previously described (Hawkins et al, 2002).
Methylation of hMLH1 was examined by bisulphite-RFLP at two
separate regions of the hMLH1 promoter (A and C) purported to
be associated with hMLH1 silencing (Herman et al, 1998; Deng
et al, 2002). The A region, encompassing base pairs 801–1050 of
the hMLH1 promoter, was amplified with the primers MLH-AF,
50-TTAYGGGTAAGTYGTTTTGAYGTAGA-30 and MLH-AR, 50-
CCTATACCTAATCTATCRCCRCCTCA-30. The C region, encom-
passing base pairs 1201–1450, was amplified with the primers
MLH-CF, 50-GGTTGGATATTTYGTATTTTTYGAG-30 and MLH-
CR, 50-AATTACTAAATCTCTTCRTCCCTCC-30. PCR was per-
formed with 100ng of bisulphite-modified template with 1mmo f
each primer, 1.5mM MgCl2, 250mM dNTPs and 1.5U FastStart
TaqDNA polymerase (Roche Diagnostics GmBH, Mannheim,
Germany) in the recommended buffer. PCR cycling conditions
were as follows: 951C for 5min; 35 cycles of 951C for 30s, 551C for
45s, 721C for 30s before a final extension at 721C for 4min. The
primers were designed to amplify both methylated and unmethy-
lated template in the same reaction. Amplicons from methylated or
unmethylated template were distinguished by restriction enzyme
digestion with 10U of BstU1. Amplicons from unmethylated
template will not cut; amplicons from methylated template will be
Table 1 Genetic and epigenetic changes in 30 CRC cell lines
Methylation
Cell line
MSI
status
APC
defect
K-ras
mutation Ploidy
MLH1
expression MLH1-A MLH1-C p16 MINT-1 MINT-2 MINT-12 MINT-31
SW620 MSS Unknown Codon 12 Aneuploid Positive U U M U P U U
C170 MSS Unknown None found Diploid Positive U U NA P U P M
COLO741 MSS None found None found Unknown ND NA U NA U M U U
COLO205 MSS Biallelic None found Aneuploid Positive U U M P M P P
SW1116 MSS Biallelic Codon 12 Unknown ND U NA M P U NA U
SW1417 MSS Biallelic Codon 13 Aneuploid ND U U U U U U U
SW403 MSS Biallelic Codon 12 Aneuploid Positive M U U U U U U
SW480 MSS Biallelic Codon 12 Aneuploid Positive U U M U M NA U
SKCO1 MSS Biallelic Codon 12 Aneuploid ND M U U P U U P
SW1222 MSS Biallelic Codon 13 Aneuploid ND U U U U M P P
COLO320DM MSS Biallelic None found Diploid Positive U U M U U P U
SW948 MSS Biallelic None found Aneuploid ND U U M P U P U
T84 MSS Biallelic Codon 13 Aneuploid Positive U U M P U P U
CACO2 MSS Biallelic None found Aneuploid Positive U U M P P P P
HT29 MSS Biallelic None found Aneuploid Positive U U M P P P P
SW837 MSS Biallelic Codon 12 Aneuploid ND U NA M P P P P
LIM1215
a MSI Unknown Codon 13 Diploid Negative U U U U U U P
LIM2412 MSI Unknown None found Diploid Negative P P M U U P U
SNU-C2B MSI Unknown Codon 12 Unknown Positive U P U P P P P
HCT8 MSI Unknown Codon 13 Diploid Positive U U M P P P U
RKO MSI Unknown None found Unknown Negative M M M P P P P
LS174T
a MSI None found Codon 12 Diploid Negative M M U U P U U
HCA7 MSI None found None found Diploid ND M M M U U U U
SW48 MSI None found None found Diploid Negative M M M P P M P
HCT116
a MSI None found Codon 13 Aneuploid Negative U U P P P P P
GP2D
a MSI Biallelic Codon 12 Diploid ND U U U P M U U
HCT15N
b MSI Biallelic Codon 13 Aneuploid Positive U U M U P P P
LOVO
c MSI Biallelic Codon 13 Diploid Positive U U M P U P P
LS411
a MSI Biallelic None found Diploid Negative P P M P U P P
DLD-1
b MSI Biallelic Codon 13 Diploid Positive U U M P P P P
aMLH1 germline mutation.
bMSH6 germline mutation. MSS=microsatellite stable; MSI=microsatellite instability; M=methylated; U=unmethylated; P=partially methylated;
NA=not amplifiable; ND=not done.
cMSH2 germline mutation.
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414digested. MLH1 expression was determined in parallel, in a subset
of 20 cell lines, by Western blot, or immunostaining, as previously
described (Ward et al, 2001; Li et al, 2002).
Methylation was reported for each locus as unmethylated,
partially methylated or methylated. For p16, partial methylation
was indicated by amplification in both the unmethylated and
methylated MS-PCR reactions. For the MINT loci and hMLH1,
partial methylation was recorded when the digestion of PCR
products was incomplete. For hMLH1, the A and C regions were
considered as one locus for analysis. Positive and negative controls
were included in each procedure, and neither control revealed
partial methylation in any assay. PCR reactions for all loci were
performed from the same bisulphite-treated reaction in the
majority of cases.
Categorical variables were compared using the w
2 test or the
Fisher exact test as appropriate. A probability value of o0.05 was
considered statistically significant. Statistical analysis was per-
formed with SPSS statistical software V9.0 (SPSS Inc., Chicago, IL,
USA).
RESULTS
The genetic and epigenetic changes in each cell line are detailed in
Table 1. Overall, 87% (24 out of 30) of cell lines demonstrated
methylation at two or more than six loci. The median number of
methylated sites was 3, and this was observed in 44% of cell lines.
Methylation at all six loci was seen in 7%. The majority of primary
tumours from HNPCC individuals displayed virtually no CpG
island hypermethylation; 6 out of 7 had less than two of the loci
methylated (Table 2). There were no significant differences,
however, in the methylation propensity of sporadic cell lines vs
germline-derived cell lines. The frequency of hypermethylation at
individual loci in both types, compared with primary tumours, is
shown in Table 3. A significant increase in the frequency of
methylation in cell lines compared to primary tumours is apparent
(Po0.01), regardless of germline status.
Methylation of p16 (Figure 1A) was present in 71% (20/28) of cell
lines assessable at this locus. One cell line, HCT116, showed partial
methylation, and this has been shown previously to be because of
the presence of a somatically mutated, but nonmethylated allele
(Myohanen et al, 1998). Methylation at p16 could not be reported
in two cell lines, COLO741 and C170, owing to the lack of
amplification of p16, and this is likely because of biallelic loss of
p16.
Methylation at the MINT loci (Figure 1B) was also a frequent
finding in most of the cell lines, and this was usually observed as
partial methylation. Partial methylation was considered real, and
not an artefact of the bisulphite reaction, as PCR reactions for all
the examined loci were usually performed from the same
bisulphite reaction. In addition, peripheral blood control DNA
was included at each step, along with all samples. Furthermore,
overdigestion with excess enzyme performed on a subset of these
partially methylated samples showed the same result. The
frequencies of MINT methylation ranged from 53 to 68%, and at
all loci the frequency was significantly higher than that observed in
sporadic CRC (Table 3). Like p16, the frequency of methylation of
MINT loci was increased in the cell lines irrespective of germline
status; only one HNPCC primary tumour displayed some
significant methylation.
Methylation of hMLH1 at either the A or C region occurred in
30% of assessable cell lines (A, 28%; C, 25%), Figure 2A. Either full
or partial methylation of both regions was strongly associated with
loss of hMLH1 expression (Po0.001), Figure 2B. Methylation of
the A or C region alone did not affect the expression of MLH1.
Only one cell line, LIM1215, showed a loss of hMLH1 expression in
the absence of promoter methylation; however, this cell line has a
germline hMLH1 mutation, and probably LOH as the second hit
(Whitehead et al, 1985).
There was only one cell line that showed no methylation at any
of the six loci–SW1417. Although this unmethylated cell line was
microsatellite stable (MSS), there was no significant association
overall of MSI and the degree of methylation. There was no
association between the methylation of any individual marker and
the presence of MSI, with the exception of hMLH1 (A or C region
methylation, P¼0.03). Apart from this expected association,
methylation overall was found to occur with approximately equal
frequency in MSS and MSI cell lines.
Microsatellite instability itself was detected in 14 cell lines
(47%), and a biallelic inactivation of APC in 18 (60%). The two
were not always mutually exclusive, with five cell lines (GP2D,
HCT15N, LOVO, LS411 and DLD-1) showing both MSI and APC
inactivation. As expected, the presence of MSI was highly
associated with diploid cell lines (P¼0.001) and APC mutants
were more likely to be aneuploid (P¼0.03). There was also a
significant association between the presence of MSI and the loss of
hMLH1 expression (P¼0.03).
A remarkably high rate of Ki-ras mutations was found in this
data set. Of the 30 cell lines, 19 (63%) were found to have a point
mutation in either codon 12 or codon 13 of Ki-ras (Figure 3).
Codon 12 mutations occurred in 33%, and this is comparable to
the expected frequency for CRC (Andreyev et al, 2001). The
Table 3 Frequency of methylation at individual loci
Loci Sporadic CRC
a n=417 (%) Cell line total n=30 HNPCC n=7 Cell line sporadic n=22 Cell line HNPCC n=8
MINT-1 25 63% (18) 29% (2) 59% (13) 63% (5)
MINT-2 29 57% (17) 14% (1) 55% (12) 63% (5)
MINT-12 29 68% (19) 0% (0) 70% (14) 63% (5)
MINT-31 14 53% (16) 0% (0) 46% (10) 75% (6)
P16 37 71% (20) 14% (1) 75% (15) 63% (5)
MLH1 33 30% (9) 29% (2) 32% (7) 25% (2)
aHawkins et al (2002).
Table 2 Methylation profile of seven HNPCC patients
Methylation
HNPCC
patient MLH1-A p16 MINT1 MINT2 MINT12 MINT31
1
a UU M U U U
2
a UU U U U U
3
b UU U U U U
4
b UU U U U U
5
b UU U U U U
6
b MM M M U U
7
b MU U U U U
ahMLH1 germline.
bhMSH2 germline.
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415proportion of cell lines harbouring mutations in codon 13 of Ki-ras
in these cell lines was 30%. This is considerably higher than the
reported frequencies of around 8.6% (Andreyev et al, 2001).
DISCUSSION
This study has revealed that methylation is very common in CRC
cell lines. Methylation at most loci was observed at a significantly
greater frequency than that expected from in vivo studies
(Hawkins et al, 2002). The reason for the excessive levels of
methylation in CRC cell lines as opposed to their primary
counterparts is unclear.
Significantly lower levels of CpG island hypermethylation were
observed in HNPCC primary tumours as compared to the sporadic
tumours. This agrees with other reports on methylation in primary
HNPCC tumours (Yamamoto et al, 2002); however, the cell lines
do not parallel this difference. The propensity for hypermethyla-
tion in the cell lines did not differ between those derived from
sporadic tumours, or HNPCC-derived tumours. The colorectal cell
lines displayed significantly higher rates of methylation than that
observed in primary CRC, whether it is sporadic, or associated
with a germline mutation.
There may be several reasons for the high levels of methylation
reported here. It is possible that it is acquired in vitro in a culture
environment, which is in some way conducive to methylation. In
support for this, one other study of methylation in 24 cell lines of
various origins found that all of the cultured cell lines exhibited
significantly more methylation at anonymous loci than the
primary malignancies that they were derived from (Smiraglia
et al, 2001). Using restriction genome landmark scanning (RLGS),
Smiraglia and colleagues concluded, however, that the three colon
cancer cell lines in their study were in fact the most similar to their
primary counterparts. Other cell lines in this study, such as head
and neck squamous cell carcinoma, had up to a 93-fold increase in
hypermethylation of RLGS fragments. The authors conclude that
most of the hypermethylation seen in cancer cell lines is because of
an intrinsic property of cell lines, as opposed to the primary
tumour from which they were derived. Tracking the epigenetic
changes from individual tumours to their establishment as cell
lines may distinguish between what, if any, is culture-induced
methylation and what existed in vivo. Unfortunately, the most
commonly used cell lines in CRC research have been established
for over 20 years, and such epigenetic profiling is likely to be
impossible now.
If methylation is occurring as a direct result of in vitro culture
conditions, then it is likely to induce changes in the cells that
render them nonrepresentative of the tumours from which they
were derived. The tumour suppressor gene p16 is commonly
methylated in a wide variety of human primary tumours and cell
lines (Herman et al, 1995; Merlo et al, 1995). Inactivation of p16
allows the cancer cell to escape senescence, and the normal cell
cycle controls, to rapidly proliferate. If methylation and inactiva-
tion were to occur in vitro, the result would be altered growth
characteristics, as compared to the parent tumour. Likewise, while
the majority of the MINT sequences have not been described as
genes, they may have important, albeit unknown, functions.
MINT31 (also known as CACNA1G) has been mapped to a
location of frequent LOH in cancer, and was found to be part of a
gene encoding a T-type calcium channel (Toyota et al, 1999b).
Such genes involved in modulating calcium signalling are likely to
be important in cancer cell proliferation and apoptosis. Genes with
important functions are often the targets of hypermethylation in
cancer, with consequences affecting many cellular pathways.
Besides methylation of p16 and CACNA1G, a high rate of
methylation of other important genes is observed in CRC. These
include hMLH1 (Kane et al, 1997; Herman et al, 1998) (mismatch
repair), O
6MGMT (Esteller et al, 2000b) (DNA repair) and p14/ARF
T84 HCT116 RKO LIM1215
M U U U M M U M MW
151
116
MW CACO2
COLO205
RKO
LIM1215
undigested
193
116
75
A
B
Figure 1 Analysis of methylation of p16 and MINT loci in colorectal cell lines. (A) For p16 promoter analysis, bisulphite-modified cell line DNA was
amplified in separate reactions using primers specific for unmethylated (U) or methylated (M) template (methylation-specific PCR - MSP). Examples of
methylated cell lines are T84 and RKO; these show amplification in the methylated reaction only. Presence of PCR product in both unmethylated and
methylated reactions of HCT116 is indicative of partial methylation at p16. LIM1215 is shown as an example of a cell line unmethylated at p16.( B) For
analysis of methylation at MINT loci, bisulphite-modified DNA was first PCR amplified using appropriate loci-specific primers, and then the PCR products
were digested with restriction enzymes that only cut amplicons generated from the methylated template. MINT2 is shown as a representative MINT locus.
Resistance to digestion indicates an unmethylated template. Shown are cell lines with partial methylation at MINT 2, CACO2 and RKO, a fully methylated
cell line, COLO205, and an unmethylated cell line LIM1215. Undigested amplicons are shown in the last lane. Molecular weight (MW) marker in A and B is
pUC19/MspI.
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416(Esteller et al, 2000a; Zheng et al, 2000) (p53 pathway). We have
also found a high rate of methylation of hMLH1 in the colon cancer
cell lines although this was one marker that was not methylated at
a higher rate in cell lines as opposed to primary tumours. It is
possible that owing to the high rate of MSI in the cell lines, there is
no selection pressure to methylate hMLH1. Methylation at both the
A and C regions of the promoter was strongly related to loss of
hMLH1 expression. This is consistent with recent reports that only
dense methylation of the hMLH1 promoter is associated with gene
silencing and loss of protein expression (Furukawa et al, 2002).
The presence of partial methylation at both the A and C regions
was also seen in cell lines lacking hMLH1 expression (LS411). This
suggests that the high rate of partial methylation seen at the MINT
loci is also functionally important. The study of p14 methylation by
Zheng and colleagues also identified partial methylation of p14
associated with reduced gene expression. Coincidentally, this study
also revealed a greater percentage of methylated p14 in cell lines
(40%) as opposed to primary colon cancers (18%).
An alternative explanation for the high frequency of methylation
observed in this study is that cell lines are more likely to be
established from those tumours that are methylated in vivo.
Tumour cell lines on the whole are difficult to establish, and
perhaps the methylator type of tumour is more amenable or
adaptable to culture conditions. Irrespective of the cause or timing
of this aberrant methylation, there is evidence to suggest that it is
important for CRC cell lines, and there is a strong selection
pressure to maintain it. For example, many in vitro studies have
shown that the methylation of various promoters is never 100%
reversible. When cultured cells with CpG island methylation are
exposed to demethylating 5-azacytidine treatments, methylation
always returns upon withdrawal of the drug in a gene-specific
manner, and has recently been shown to return, and be
hereditable, in a parental allele-specific fashion (Li et al, 2002).
This could argue that the hypermethylation present in these cell
lines is not a phenomenon of culture, but rather a necessary and
characteristic component of the cell line and the tumour from
which it was derived.
Regardless of the cause of the excessive methylation in CRC cell
lines, the end result is the same and CRC cell lines may only serve
as a model for a subset of tumours. Considering that genes
commonly methylated in CRC are often involved in cell prolifera-
tion, apoptosis and DNA repair, there is likely to be a very skewed
bias of cell lines in many areas of research, not only methylation
studies. A bias within these cell lines is further supported by the
increased frequency of Ki-ras mutations and the over-representa-
tion of MSI.
MSI occurs at a frequency of 10–15% in sporadic CRC, but was
observed at double the frequency in the sporadic cell lines. It was
not surprising to find that the MSI cell lines in this study had a
high frequency of methylation, as the association between the two
phenomena has been well reported (Toyota et al, 1999a, 2000;
Hawkins et al, 2002). What was more surprising was the high
frequency of methylation in MSS cell lines. The fact that
methylation can coexist with APC mutations in sporadic CRC
has been reported by others, albeit with a lesser frequency (Gayet
et al, 2001; Hawkins et al, 2002). These findings argue against the
hypothesis that methylation is a third distinct pathway of
colorectal tumourigenesis, and in favour of it being a feature of
both standard pathways. Whether promoter methylation is a cause
or a consequence of either pathway cannot be determined by this
study.
MW - 12 3 4 PB
155
66
45
40
140
70
A region
C region
U M PMU
UU P M U
SW480 RKO LS411 HCT116
hMLH1
A
B
Figure 2 Analysis of hMLH1 methylation and expression in colorectal
cell lines. (A) Both the A region (top panel) and C region (bottom panel)
of the hMLH1 promoter were amplified from bisulphite-treated DNA.
BstU1 restriction enzyme digest was performed to distinguish amplicons
from methylated or unmethylated template; BstU1 will cut only amplicons
generated from methylated template. Undigested PCR product is shown in
the control lane (-). Lane 1 shows an example of a cell line unmethylated at
both the A and C regions, DLD1. Lane 2 shows SW403 that is methylated
at the A region, but not C. Lane 3 shows LS411 that is partially methylated
at both regions and Lane 4 shows a fully methylated cell line, RKO.
Peripheral blood (PB) DNA used as a control is always unmethylated at
both the A and C regions. MW market is pUC19/MspI. (B) Representative
Western blot analysis of hMLH1 expression in colorectal cell lines with
various combinations of A and C region methylations. SW480 has no
methylation at either region and has wild-type hMLH1. HCT116 also is
unmethylated at both regions; however, this cell line has a frameshift
mutation in one allele of hMLH1, leading to a reduction in expression levels.
Cell lines exhibiting either full (RKO) or partial (LS411) methylation at both
the A and C regions show a loss of hMLH1 protein.
MW RKO
LS174T
HCT116
LIM1215
undigested
153
128
Figure 3 Detection of mutations in codon 13 of Ki-ras in colorectal cell
lines. RFLP analysis was performed on Ki-ras PCR amplicons with the
restriction enzyme BslI. Mutations in the first or second base of codon 13
will abolish the BslI site; therefore Ki-ras codon 13 mutants are resistant to
digestion. Wild-type (WT) amplicons, and mutants other than codon 13,
are fully digested by BslI. Undigested amplicons are shown in the last lane.
Both LIM1215 and RKO have WT Ki-ras; LS174T is a codon 12 mutant;
HCT116, displaying undigested product, is a codon 13 mutant. MW is
pUC19/MspI.
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417The high rate of Ki-ras codon 13 mutations in this study is also
worthy of mention in terms of methylation. There is a reported
association between Ki-ras mutations and highly methylated
tumours (Toyota et al, 2000; Hawkins et al, 2002), however, codon
12 mutations are the predominating type in these studies of
sporadic colorectal tumours. A high frequency of codon 13
mutations has only been reported once before, in a set of HNPCC
tumours with MSI (Fujiwara et al, 1998). This is reflected in the
germline-derived cell lines in this study; however, a significant
proportion of codon 13 mutations also occurred in Ki-ras of
nongermline cell lines. The increased frequency of codon 13
mutations in the cell lines, regardless of germline status, may in
part be explained by a methylator phenotype. It has recently been
shown that methylation of O
6-MGMT associates with Ki-ras
mutations in CRC (Esteller et al, 2000b; Whitehall et al, 2001).
This is likely because of the increased rate of G to A transition
mutations caused by the silencing, and subsequent deficiency, of
O
6-MGMT. It is also worthy of note that Ki-ras mutations have
been found to associate with p16 methylation in colorectal
tumours and adenomas (Guan et al, 1999). These results together
provide further evidence to support the notion that CRC cell lines
are predominantly representative only of the methylator type of
CRC.
Whether cause or consequence, epiphenomenon or true
epigenetic change, the high frequency of methylation in these cell
lines exists, and should be taken into account in studies on the
biology of CRC. We would suggest that cell lines may be good
models for the methylator type of CRC, and are not generally
representative of sporadic CRC.
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